Beta Carotene

Evidence Level: L4

Predicted Indications: 10

Beta Carotene

Pharmacist Assessment Report

Beta Carotene: From an Unspecified Original Indication to Acne (disease)

One-Sentence Summary

Beta carotene is a provitamin A carotenoid with antioxidant activity. It is currently marketed in Canada only as a component of pregnancy multivitamin products, and no formal approved indication text is available. The TxGNN model predicts it may be effective for acne (disease), but there are no registered clinical trials and only 7 publications, none of which tested beta carotene as an acne treatment. The evidence is therefore weak, and the prediction is best treated as a research hypothesis.

Quick Overview

Item	Content
Original Indication	Not available (no approved indication text in the Canadian licence records)
Predicted New Indication	Acne (disease)
TxGNN Prediction Score	0.9999
Evidence Level	L4
Canada Market Status	Marketed (marketed DINs: 2 of 4; dormant: 2)
Number of DINs	4 (marketed: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, beta carotene is a provitamin A carotenoid with antioxidant properties, and it is marketed in Canada within multivitamin products. Mechanistically, it may be relevant to acne.

Acne vulgaris has been linked to oxidative stress and altered vitamin A and antioxidant status. This gives a plausible but indirect link between an antioxidant and vitamin A precursor and acne.

The available literature consists mainly of observational antioxidant and serum-level studies, studies of plant extracts, and a study of isotretinoin-induced oxidative toxicity. No study has tested beta carotene as an acne treatment. The very high TxGNN score (0.99999) is a model output and is not supported by clinical data.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
20049267	2009	Cross-sectional	Indian J Dermatol	Oxidant/antioxidant status was assessed in obese adolescent females with acne vulgaris.
22517509	2012	Cohort	Cell Biochem Funct	Pilot study of plasma antioxidant vitamins and oxidative markers in acne patients before and after isotretinoin; the treatment induced oxidative toxicity.
7618499	1995	Review	J Am Board Fam Pract	General review of vitamins and their derivatives used as therapy.
2073211	1990	Review	Australas J Dermatol	Skin abnormalities in 14 anorexia nervosa patients, including elevated beta-carotene levels and acne in a small subset.
4230169	1967	Cross-sectional	Dermatol Wochenschr	Serum vitamin A and beta-carotene levels in people with and without skin diseases.
39459015	2024	In vitro	Pharmaceuticals (Basel)	Antioxidant and antibacterial properties of ylang-ylang essential oil with potential dermatological use (not beta carotene).
23625436	2013	In vitro	Pak J Pharm Sci	Antioxidant and antibacterial activity of Helichrysum oligocephalum extracts (not beta carotene).

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02535718	PREGNANCY MULTIVITAMIN	Not specified	Not specified
02552620	PREGVIT	Not specified	Not specified
02537478	PREGNANCY MULTIVITAMIN FOLIC 5	Not specified	Not specified
02552639	PREGVIT FOLIC 5	Not specified	Not specified

Safety Considerations

Disease associations flagged by the knowledge graph (not label text): The TxGNN knowledge graph lists contraindication links with blood coagulation disease, sickle cell anemia, hereditary persistence of fetal hemoglobin, primary hyperoxaluria, hereditary hemochromatosis, hemosiderosis, iron metabolism disease, and Wilson disease. These come from a model knowledge graph and should be verified against the official product labelling.
Drug Interactions: Two interactions were identified.
- Verteporfin: Moderate
- Lutein: Minor

Please refer to the package insert for warnings and contraindications from the label, as these were not available for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a very high model score and an indirect antioxidant rationale. There are no clinical trials, and no study has tested beta carotene as an acne treatment. The evidence is graded L4, and the label safety information needed for safety screening is missing.

To proceed, the following is needed:

The Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
Mechanism of action data (for example, from DrugBank)
Interventional studies of beta carotene in acne, or at least controlled data comparing acne patients with healthy controls
Clarification of the original approved indication and dosage forms for the Canadian products
Review of the similarities the TxGNN model (deep learning) learned between related diseases (such as iron metabolism disorders and Wilson disease) against labelling; these reflect learned similarities, not biological evidence

Note on Other Predicted Indications

The data compiled for this report also include other predictions with the same or lower evidence strength:

Diabetic retinopathy (L4): Evidence is preclinical (diabetic rodent models) and observational, with no clinical trials. It is classed as a research question.
Cortical cataract (L3): Interventional data exist, including the ATBC trial substudy (PMID 9527321). They did not show a clear benefit from beta carotene, and this is classed as a research question.
Diabetic cataract and type 2 diabetes-associated cataract (L4): Only observational or general literature is available.
Severe nonproliferative diabetic retinopathy, nuclear senile, mature, tetanic and immature cataract (L5): Model prediction only, with no supporting studies. For mature and tetanic cataract, the antioxidant rationale is also unlikely to be relevant.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.